These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22033197)

  • 21. Topochemical models for the prediction of permeability through blood-brain barrier.
    Dureja H; Madan AK
    Int J Pharm; 2006 Oct; 323(1-2):27-33. PubMed ID: 16815653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells.
    Hakkarainen JJ; Pajander J; Laitinen R; Suhonen M; Forsberg MM
    Int J Pharm; 2012 Oct; 436(1-2):426-43. PubMed ID: 22750947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapidly profiling blood-brain barrier penetration with liposome EKC.
    Wang Y; Sun J; Liu H; He Z
    Electrophoresis; 2007 Jul; 28(14):2391-5. PubMed ID: 17578839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro models for the blood-brain barrier.
    Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
    Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel models for assessing blood-brain barrier drug permeation.
    Geldenhuys WJ; Allen DD; Bloomquist JR
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):647-53. PubMed ID: 22468700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling of the blood-brain barrier in drug discovery and development.
    Cecchelli R; Berezowski V; Lundquist S; Culot M; Renftel M; Dehouck MP; Fenart L
    Nat Rev Drug Discov; 2007 Aug; 6(8):650-61. PubMed ID: 17667956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the blood-brain barrier in CNS drug discovery.
    Jeffrey P; Summerfield S
    Neurobiol Dis; 2010 Jan; 37(1):33-7. PubMed ID: 19664709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling blood-brain barrier partitioning using Bayesian neural nets.
    Winkler DA; Burden FR
    J Mol Graph Model; 2004 Jul; 22(6):499-505. PubMed ID: 15182809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
    Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
    Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.
    Steuer H; Jaworski A; Elger B; Kaussmann M; Keldenich J; Schneider H; Stoll D; Schlosshauer B
    Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):1047-53. PubMed ID: 15728564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening.
    Culot M; Lundquist S; Vanuxeem D; Nion S; Landry C; Delplace Y; Dehouck MP; Berezowski V; Fenart L; Cecchelli R
    Toxicol In Vitro; 2008 Apr; 22(3):799-811. PubMed ID: 18280105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applicability of a blood-brain barrier specific artificial membrane permeability assay at the early stage of natural product-based CNS drug discovery.
    Könczöl A; Müller J; Földes E; Béni Z; Végh K; Kéry A; Balogh GT
    J Nat Prod; 2013 Apr; 76(4):655-63. PubMed ID: 23565574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Murine in vitro model of the blood-brain barrier for evaluating drug transport.
    Shayan G; Choi YS; Shusta EV; Shuler ML; Lee KH
    Eur J Pharm Sci; 2011 Jan; 42(1-2):148-55. PubMed ID: 21078386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration.
    Trapa PE; Belova E; Liras JL; Scott DO; Steyn SJ
    J Pharm Sci; 2016 Feb; 105(2):965-971. PubMed ID: 26869440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating the utility of momentum-space descriptors for predicting blood-brain barrier penetration.
    Al-Fahemi JH; Cooper DL; Allan NL
    J Mol Graph Model; 2007 Oct; 26(3):607-12. PubMed ID: 17300970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
    Kalvass JC; Polli JW; Bourdet DL; Feng B; Huang SM; Liu X; Smith QR; Zhang LK; Zamek-Gliszczynski MJ;
    Clin Pharmacol Ther; 2013 Jul; 94(1):80-94. PubMed ID: 23588303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.
    Cucullo L; Hossain M; Rapp E; Manders T; Marchi N; Janigro D
    Epilepsia; 2007 Mar; 48(3):505-16. PubMed ID: 17326793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.